Verdiva joins crowded GLP-1 space, launches with $411M series A

Jan. 9, 2025

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and a portfolio of GLP-1 and amylin agonists in-licensed from China.

BioWorld Financings Newco news Cardiovascular Endocrine/metabolic Obesity Small molecule Series A Europe U.S.

Today's news in brief

BioWorld

BioWorld briefs for April 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 16, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Capsules and tablets scattered over a world map

Biopharma tariffs becoming more than a threat

BioWorld

U.S. tariffs on biopharmaceuticals have advanced beyond administration talking points.As a precursor to tariffs, Commerce Secretary Howard Lutnick initiated an...

New Trump order zeroes in on drug prices

BioWorld

In a blast from the past, U.S. President Donald Trump signed an executive order April 15 to deliver on his 2016 campaign promises and strengthen or reinstate...